Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 20 - Menopause

References

1. Fritz M, Speroff L. Menopause and the perimenopause. Chapter 17. In: Clinical Gynecologic Endocrinology and Infertility, 8th edition. Philadelphia: Wolters Klower; 2011. p 674–748.
2. Fritz M, Speroff L. Post menopausal hormone therapy. CHapter 18. In: Clinical Gynecologic Endocrinology and Infertility, 8th edition. Philadelphia: Wolters Klower: 2011. p 749–857.
3. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1–s66.
4. American Association of Clinical Endocrinologists (AACE). In: Cobin RH, Petak SM (Eds.). Position Statement on Hormone Replacement Therapy (HRT) and Cardiovascular Risk. 2011 www.aace.com/.
5. Harlow SD, Gass M, Hall JE, et al. STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop addressing the unfinished agenda of stages of reproductive aging. Fertil Steril. 2012;97(4):843–51.
6. Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab. 2011;96(2):255–64.
7.US Census Bureau Report. Table 2. www.census.gov/prof/cen2010/docsf1
8. Oktem O, Urman B. Understanding follicle growth in vivo. Hum Reprod. 2010;25(12):2944–54.
9. Voorhuis M, Broekmans FJ, Fauser BC, et al. Genes involved in initial follicle recruitment may be associated with age at menopause. J Clin Endocrinol Metab. 2011;96(3):E473–9.
10. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol. 2001;153(9):865–74.
11. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman’s reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab. 1998;83:1875–80.
12. Therman E, Laxova R, Susman B. The critical region on the human Xq. Hum Genet. 1990;85(5):455–61.
13. Sala C, Arrigo G, Torri G, et al. Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21. Genomics. 1997;40(1):123–31.
14. Stolk L, Perry JR, Chasman DI, et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet. 2012;44(3):260–8.
15. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med. 1985;103(3):350–6.
16. Tylavsky FA, Anderson JJ. Dietary factors in bone health of elderly lactoovovegetarian and omnivorous women. Am J Clin Nutr. 1988;48(3 Suppl):842–9.
17. McKinlay SM, Bifano NL, McKinlay JB. The normal menopause transition. Maturitas. 1992;14(2):103–15.
18. Treloar AE. Menarche, menopause, and intervening fecundability. Hum Biol. 1974;46(1):89–107.
19. Luborsky JL, Meyer P, Sowers MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199–206.
20. Gosden RG, Faddy MJ. Ovarian aging, follicular depletion, and steroidogenesis. Exp Gerontol. 1994;29(3–4):265–74.
21. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000;21(2):200–14.
22. WHO Scientific Group: Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1996;866:1–79. Geneva, Switzerland: World Health Organization.
23. Randolph JF Jr, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96(3):746–54.
24. Faddy MJ, Gosden RG, Gougeon A, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342–6.
25. Randolph JF Jr, Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab. 2006;91(8):3034–40.
26. Neugarten BL, Kraines RJ. Menopausal symptoms in women of various ages. Psychosom Med. 1965;27:266–73.
27. Ballinger CB, Browning MC, Smith AH. Hormone profiles and psychological symptoms in peri-menopausal women. Maturitas. 1987;9(3):235–51.
28. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52–86; discussion 123–33.
29. Iqbal J, Blair HC, Zallone A, Sun L, Zaidi M. Further evidence that FSH causes bone loss independently of low estrogen. Endocrine. 2012;41(2):171–5.
30. Sowers M, Crutchfield M, Bandekar R, et al. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res. 1998;13(7):1134–40.
31. Barbieri RL. Managing the Perimenopause. Washington DC: APGO; 2001.
32. Kase NG. Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. Gend Med. 2009;6(Suppl 1):37–59.
33. Longcope C, Franz C, Morello C, et al. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas. 1986;8(3):189–96.
34. Longcope C, Jaffee W, Griffing G. Production rates of androgens and oestrogens in post-menopausal women. Maturitas. 1981;3(3–4):215–23.
35. Burger HG, Dudley EC, Cui J, et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85(8):2832–8.
36. Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril. 1994;62(1):20–7.
37. Janssen I, Powell LH, Crawford S, et al. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med. 2008;168(14):1568–75.
38. Feldman S, Shapter A, Welch WR, et al. Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy. Gynecol Oncol. 1994;55(1):56–9.
39. Kroon E, Andolf E. Diagnosis and follow-up of simple ovarian cysts detected by ultrasound in postmenopausal women. Obstet Gynecol. 1995;85(2):211–14.
40. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
41. Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008;11(1):32–43.
42. Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009;16(3):453–7.
43. Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas. 1997;27(3):203–14.
44. Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Climacteric. 2007;10(4):320–34.
45. Holland EF, Studd JW, Mansell JP, et al. Changes in collagen composition and cross-links in bone and skin of osteoporotic postmenopausal women treated with percutaneous estradiol implants. Obstet Gynecol. 1994;83(2):180–3.
46. Avis NE, Brambilla D, McKinlay SM, et al. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women’s Health Study. Ann Epidemiol. 1994;4(3):214–20.
47. Busch CM, Zonderman AP, Costa PT. Menopausal transition and psychological distress in a nationally representative sample: Is menopause associated with psychological distress? J Aging Health. 1994;6:209–28.
48. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4):375–82.
49. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63(4):385–90.
50. Bromberger JT, Kravitz HM, Matthews K, et al. Predictors of first lifetime episodes of major depression in midlife women. Psychol Med. 2009;39(1):55–64.
51. Osterlund MK. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim Biophys Acta. 2010;1800(10):1136–44.
52. Kawai M, Mödder UI, Khosla S, et al. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov. 2011;10(2):141–56.
53. National Osteoporosis Foundation. http://www.nof.org/prof/ 2009.
54. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
55. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529–39.
56. Trémollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int. 2001;12(5):385–96.
57. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104(3):443–51.
58. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.
59. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221–30.
60. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–61.
61. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.
62. Rosen CJ. The role of parathyroid hormone in the management of osteoporosis. Horm Res. 2005; 64(Suppl 2):81–5.
63. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.
64. Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31(1):56–60.
65. Tankó LB, Søndergaard BC, Oestergaard S, et al. An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage. Climacteric. 2008;11(1):4–16.
66. Cirillo DJ, Wallace RB, Wu L, et al. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum. 2006;54(10):3194–204.
67. Semmens JP, Tsai CC, Semmens EC, et al. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol. 1985;66(1):15–18.
68. Yamaguchi O, Nishizawa O, Takeda M, et al. For the Neurogenic Bladder Society. Clinical guidelines for overactive bladder. Int J Urol. 2009;16(2):126–42.
69. Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131.
70. Preisinger E, Alacamlioglu Y, Saradeth T, et al. Forearm bone density and grip strength in women after menopause, with and without estrogen replacement therapy. Maturitas. 1995;21(1):57–63.
71. Naessen T, Lindmark B, Larsen HC. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol. 1997;177(2):412–6.
72. Meyer PM, Powell LH, Wilson RS, et al. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology. 2003;61(6):801–16.
73. Smith YR, Giordani B, Lajiness-O’Neill R, et al. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. Fertil Steril. 2001;76(6):1101–7.
74. Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry. 2001;158(2):227–33.
75. Yaffe K, Haan M, Byers A, et al. Estrogen use, APOE, and cognitive decline: evidence of gene–environment interaction. Neurology. 2000;54(10):1949–54.
76. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48(6):1517–21.
77. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology. 1998;50(4):996–1002.
78. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet. 1996;348(9025):429–32.
79. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651–62.
80. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2959–68.
81. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288(17):2123–9.
82. Crawford SL, Casey VA, Avis NE, et al. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women’s Health Study. Menopause. 2000;7(2):96–104.
83. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7.
84. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307(5):483–90.
85. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):2404–11.
86. de Luca C, Olefsky JM. Stressed out about obesity and insulin resistance. Nat Med. 2006;12(1):41–2; discussion 42.
87. National Health Statistics Reports #13, 2009.
88. St. Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care. 2004;27(9):2222–8.
89. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.
90. ADA Statistical Reports. 2011.
91. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–9.
92. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321(10):641–6.
93. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20(8):1998–2004.
94. Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med. 2011;364(14):1315–25.
95. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1804–11.
96. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308(5728):1583–7.
97. Anasti JN, Kalantaridou SN, Kimzey LM, et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1998;91(1):12–15.
98. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19(7):791–804.
99. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.
100. National Cancer Institute. Surveillance Epidemiology and End Results. http://seer cancer.gov/car/1975-2000/. (accessed April 6, 2012).
101. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670–4.
102. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672–94.
103. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–41.
104. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.
105. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193–201.
106. Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer – a pooled analysis. N Engl J Med. 1996;334(6):356–61.
107. Maruti SS, Willett WC, Feskanich D, et al. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst. 2008;100(10):728–37.
108. Thiébaut AC, Kipnis V, Chang SC, et al. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst. 2007;99(6):451–62.
109. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women’s Health Initiative Cohort Study. JAMA. 2003;290(10):1331–6.
110. Thune I, Brenn T, Lund E, et al. Physical activity and the risk of breast cancer. N Engl J Med. 1997;336(18):1269–75.
111. Brinton LA, Bernstein L, Colditz GA. Summary of the workshop: Workshop on Physical Activity and Breast Cancer, November 13–14, 1997. Cancer. 1998;83(3 Suppl):595–9.
112. Friedenreich CM, Bryant HE, Courneya KS. Case-control study of lifetime physical activity and breast cancer risk. Am J Epidemiol. 2001;154(4):336–47.
113. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology. 2011;152(7):2546–51.
114. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.
115. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–44.
116. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–77.
117. Wu HK, Squire JA, Catzavelos CG, et al. Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun. 1997;235(1):123–9.
118. Tamimi RM, Colditz GA, Wang Y, et al. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat. 2011;128:243–50.
119. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19(5):3278–88.
120. Masur K, Vetter C, Hinz A, et al. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer. 2011;104(2):345–52.
121. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909–15.
122. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.
123. DuSell CD, Umetani M, Shaul PW, et al. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22(1):65–77.
124. Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465(7299):798–802.
125. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133(12):933–41.
126. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591–602.
127. Løkkegaard E, Jovanovic Z, Heitmann BL, et al. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study. Arch Neurol. 2003;60(10):1379–84.
128. Li C, Engström G, Hedblad B, et al. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas. 2006;54(1):11–18.
129. Finucane FF, Madans JH, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med. 1993;153(1):73–9.
130. Seely EW, Walsh BW, Gerhard MD, et al. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension. 1999;33(5):1190–4.
131. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
132. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.
133. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–34.
134. Stefanick ML, Cochrane BB, Hsia J, et al. The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9 Suppl):S78–86.
135. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348(19):1839–54.
136. Appt SE, Clarkson TB, Lees CJ, et al. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas. 2006;55(2):187–94.
137. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133(12):933–41.
138. Lethbridge-Cejku M, Schiller JS, Bernadel L. Summary health statistics for U.S. adults: National Health Interview Survey, 2002. Vital Health Stat 10. 2004;(222):1–151.
139. Lisabeth LD, Beiser AS, Brown DL, et al. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke. 2009;40(4):1044–9.
140. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6.
141. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–84.
142. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425–34.
143. Grodstein F, Manson JE, Stampfer MJ, et al. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med. 2008;168(8):861–6.
144. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.
145. Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric. 2010;13(5):429–32.
146. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011;124(3):199–205.
147. Santen RJ, Allred DC. The estrogen paradox. Nat Clin Pract Endocrinol Metab. 2007;3:496–7.
148. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647–57.
149. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006;166(9):1027–32.
150. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update. 2005;11(6):561–73.
151. Welch HG, Black WC, Welch HE. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127(11):1023–8.
152. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol. J Natl Cancer Inst. 2001;93(22):1714–23.
153. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91(3):264–70.
154. Jernström H, Frenander J, Fernö M, et al. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer. 1999;80(9):1453–8.
155. Christante D, Pommier S, Garreau J, et al. Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg. 2008;196(4):505–11.
156. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1739–48.
157. Jaakkola S, Lyytinen H, Pukkala E, et al. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol. 2009;114(6):1197–204.
158. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73.
159. Mørch LS, Løkkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. JAMA. 2009;302(3):298–305.
160. Rossing MA, Cushing-Haugen KL, Wicklund KG, et al. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2548–56.
161. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009;374(9697):1243–51.
162. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106(5):574–82.
163. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2609–18.
164. Irwin RW, Yao J, Ahmed SS, et al. Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Endocrinology. 2011;152(2):556–67.
165. Bethea CL. MPA: medroxy-progesterone acetate contributes to much poor advice for women. Endocrinology. 2011;152(2):343–5.
166. Turgeon JL, McDonnell DP, Martin KA, et al. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004;304(5675):1269–73.
167. Manson J, Bassuk S. The menopause transition and postmenopausal hormone therapy. In: Kasper DL, Braunwald E, Fauci AS, et al. (Eds.). Harrison’s Principles of Internal Medicine, 17th edition. New York: McGraw-Hill, 2005, pp. 3040–5.